LIVIVO - Search results -

Search results

Result 1 - 10 of total 20

Search options

Article ; Online: A Case of Burkitt’s Lymphoma Mimicking Peritonitis Carcinomatosa

Büyüktaş, Deram / Örnek, Serdar / Tecimer, Tülay / Ferhanoğlu, Burhan

Turkish journal of haematology : official journal of Turkish Society of Haematology

2020 Volume 37, Issue 3, Page(s) 215–216

MeSH term(s)	Adult ; Burkitt Lymphoma/diagnostic imaging ; Burkitt Lymphoma/drug therapy ; Humans ; Male ; Peritoneal Neoplasms/diagnostic imaging ; Peritoneal Neoplasms/drug therapy ; Positron Emission Tomography Computed Tomography
Language	English
Publishing date	2020-03-17
Publishing country	Turkey
Document type	Case Reports ; Journal Article
ZDB-ID	2185903-6
ISSN	1308-5263 ; 1300-7777
ISSN (online)	1308-5263
ISSN	1300-7777
DOI	10.4274/tjh.galenos.2020.2020.0015
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6534: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: IRF4

Büyüktaş, Deram / Örnek, Serdar / Tokat, Fatma / Tecimer, Tülay / Ferhanoğlu, Burhan

Turkish journal of haematology : official journal of Turkish Society of Haematology

2020 Volume 37, Issue 4, Page(s) 292–294

Language	English
Publishing date	2020-04-29
Publishing country	Turkey
Document type	Journal Article
ZDB-ID	2185903-6
ISSN	1308-5263 ; 1300-7777
ISSN (online)	1308-5263
ISSN	1300-7777
DOI	10.4274/tjh.galenos.2020.2020.0086
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6534: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: COVID-19 infection in patients with acute leukemia; Istanbul experience.

Buyuktas, Deram / Acar, Kadir / Sucak, Gulsan / Toptas, Tayfur / Kapucu, Irem / Bekoz, Huseyin / Erdem, Simge / Nalcaci, Meliha / Atalay, Figen / Akay, Meltem Olga / Ferhanoglu, Burhan

American journal of blood research

2021 Volume 11, Issue 4, Page(s) 427–437

Abstract: Coronavirus disease 2019 (COVID-19) has led to a global pandemic that has also challenged the management of various other life-threatening conditions, such as malignant disorders. In this study, we present the clinical features and treatment outcomes of ... ...

Abstract	Coronavirus disease 2019 (COVID-19) has led to a global pandemic that has also challenged the management of various other life-threatening conditions, such as malignant disorders. In this study, we present the clinical features and treatment outcomes of twenty-seven COVID-19 positive patients with leukemia across seven different centers in Istanbul. From March 1st to December 31st 2020, 116 patients were diagnosed with acute leukemia. Thirty-two cases with acute lymphocytic leukemia (ALL), 82 cases with acute myeloid leukemia (AML), and 2 cases with mixed phenotype acute leukemia (MPAL) were identified. Of the 27 patients with the COVID-19 infection, seven patients had ALL, 19 patients had AML and one patient had MPAL. The mortality rate was 37% among the patients with AML, whereas there were no deaths in the ALL group. The mortality rate of AML patients with the COVID-19 infection was higher compared to cases without the infection (P<0.05). We could not detect any significant difference in the ALL cohort. This study, which includes one of the largest acute leukemia series in literature proved that acute myeloid leukemia patients with the COVID-19 infection have worse outcomes than patients without the infection. The high mortality among patients with acute leukemias hospitalized with COVID-19 highlight the need for aggressive infection prevention, increased surveillance and protective isolation and even modification of the therapy, in case of minimal residual disease (MRD) negativity.
Language	English
Publishing date	2021-08-15
Publishing country	United States
Document type	Journal Article
ZDB-ID	2620435-6
ISSN	2160-1992
ISSN	2160-1992
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Postoperative thrombotic thrombocytopenic purpura.

Eskazan, Ahmet Emre / Buyuktas, Deram / Soysal, Teoman

Surgery today

2013 Volume 45, Issue 1, Page(s) 8–16

Abstract: Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening disease characterized by acute episodes of thrombocytopenia and microangiopathic hemolytic anemia occurring due to platelet and von Willebrand factor deposition and hyaline thrombi ... ...

Abstract	Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening disease characterized by acute episodes of thrombocytopenia and microangiopathic hemolytic anemia occurring due to platelet and von Willebrand factor deposition and hyaline thrombi formation in arterioles and capillaries throughout the body, which results in organ ischemia. TTP can be idiopathic or secondary, and there are several causes of secondary TTP. There is a clinical syndrome resembling TTP that occurs after surgical procedures, so-called "postoperative TTP" (pTTP). In this review, the differential diagnosis, pathogenesis and clinical and laboratory features of pTTP, together with the treatment modalities and outcomes of the patients, are discussed. The pTTP is a diagnosis of exclusion, and disseminated intravascular coagulation, heparin-induced thrombocytopenia and medication-induced effects should be ruled out. As in classical TTP, patients with pTTP should be diagnosed and treated with therapeutic plasma exchange (TPE) as early as possible to reduce their morbidity and mortality. Although rarely seen, surgeons and physicians of all specialties should be alert to the possibility of pTTP, and since pTTP is a life-threatening event that usually can be treated successfully with TPE, especially when diagnosed early in its course, it is critical to recognize and treat pTTP promptly.
MeSH term(s)	ADAM Proteins/blood ; ADAMTS13 Protein ; Biomarkers/blood ; Diagnosis, Differential ; Early Diagnosis ; Humans ; Plasma Exchange ; Postoperative Complications/diagnosis ; Postoperative Complications/etiology ; Postoperative Complications/therapy ; Purpura, Thrombotic Thrombocytopenic/diagnosis ; Purpura, Thrombotic Thrombocytopenic/etiology ; Purpura, Thrombotic Thrombocytopenic/therapy ; Treatment Outcome
Chemical Substances	Biomarkers ; ADAM Proteins (EC 3.4.24.-) ; ADAMTS13 Protein (EC 3.4.24.87) ; ADAMTS13 protein, human (EC 3.4.24.87)
Language	English
Publishing date	2013-12-29
Publishing country	Japan
Document type	Journal Article ; Review
ZDB-ID	1115435-4
ISSN	1436-2813 ; 0941-1291
ISSN (online)	1436-2813
ISSN	0941-1291
DOI	10.1007/s00595-013-0823-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.B 1077: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Poland syndrome associated with pernicious anemia and gastric dysplasia.

Aytaç, Erman / Durgun, Ali Vedat / Büyüktaş, Deram / Büyüktaş, Deram / Erdamar, Sibel / Ongören, Seniz

Turkish journal of haematology : official journal of Turkish Society of Haematology

2012 Volume 29, Issue 4, Page(s) 441–444

Language	English
Publishing date	2012-12-05
Publishing country	Turkey
Document type	Journal Article
ZDB-ID	2185903-6
ISSN	1308-5263 ; 1300-7777
ISSN (online)	1308-5263
ISSN	1300-7777
DOI	10.5505/tjh.2012.39259
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6534: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Ornithine transcarbamylase deficiency diagnosed in pregnancy.

Celik, Ozlem / Buyuktas, Deram / Aydin, Ahmet / Acbay, Ozer

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

2011 Volume 27, Issue 12, Page(s) 1052–1054

Abstract: Urea cycle enzymes deficiencies are rare metabolic disorders. Ornithine transcarbamylase (OTC) deficiency is the most common type. The syndrome results from a deficiency of the mitochondrial enzyme OTC which catalyses the conversion of ornithine and ... ...

Abstract	Urea cycle enzymes deficiencies are rare metabolic disorders. Ornithine transcarbamylase (OTC) deficiency is the most common type. The syndrome results from a deficiency of the mitochondrial enzyme OTC which catalyses the conversion of ornithine and carbamoyl phosphate to citrulline. It shows X-linked inheritance and typically remains asymptomatic until late infancy or early childhood. The severity of the symptoms depends on the age of the patient and the duration of hyperammonemia. Female heterozygotes are more difficult to diagnose. They suffer from hyperammonemic periods which can be triggered by trauma, infections, surgery, childbirth, parenteral nutrition, and by the initiation of sodium valproate therapy. The prognosis of OTC deficiency is better for those with an onset after infancy, but morbidity from brain damage does not appear to be linked to the number of episodes of hyperammonemia that have occurred. However, early diagnosis and prompt initiation of ammonia-lowering treatment are essential for survival of these patients. This case presents a patient who was diagnosed with OTC deficiency following mental confusion during pregnancy.
MeSH term(s)	Adult ; Age of Onset ; Epilepsy/diagnosis ; Epilepsy/etiology ; Female ; Humans ; Ornithine Carbamoyltransferase Deficiency Disease/complications ; Ornithine Carbamoyltransferase Deficiency Disease/diagnosis ; Ornithine Carbamoyltransferase Deficiency Disease/epidemiology ; Pregnancy ; Pregnancy Complications/diagnosis ; Pregnancy Complications/epidemiology
Language	English
Publishing date	2011-12
Publishing country	England
Document type	Case Reports ; Journal Article
ZDB-ID	639237-4
ISSN	1473-0766 ; 0951-3590
ISSN (online)	1473-0766
ISSN	0951-3590
DOI	10.3109/09513590.2011.569787
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2284: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 608: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Book ; Online ; Thesis: Zytogenetische und klinische Verläufe von älteren Patienten mit fortgeschrittenem MDS unter alleiniger 5-Azacytidin-Therapie im Vergleich zur Therapie mit 5-Azacytidin gefolgt von allogener Stammzelltransplantation

Büyüktas, Deram [Verfasser] / Schanz, Julie [Akademischer Betreuer] / Ströbel, Philipp [Gutachter] / Oppermann, Martin [Gutachter]

2018

Author's details	Deram Büyüktas ; Gutachter: Philipp Ströbel, Martin Oppermann ; Betreuer: Julie Schanz
Keywords	Medizin, Gesundheit ; Medicine, Health
Subject code	sg610
Language	German
Publisher	Niedersächsische Staats- und Universitätsbibliothek Göttingen
Publishing place	Göttingen
Document type	Book ; Online ; Thesis
Database	Digital theses on the web

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Fatigue is correlated with disease activity but not with the type of organ involvement in Behçet's syndrome: a comparative clinical survey.

Buyuktas, Deram / Hatemi, Gulen / Yuksel-Findikoglu, Sukran / Ugurlu, Serdal / Yazici, Hasan / Yurdakul, Sebahattin

Clinical and experimental rheumatology

2015 Volume 33, Issue 6 Suppl 94, Page(s) S107–12

Abstract: Objectives: Fatigue is an important problem in inflammatory diseases and affects the quality of life (QoL). We aimed to evaluate the severity and impact of fatigue in Behçet's syndrome (BS) and to determine its association with type of organ involvement ...

Abstract	Objectives: Fatigue is an important problem in inflammatory diseases and affects the quality of life (QoL). We aimed to evaluate the severity and impact of fatigue in Behçet's syndrome (BS) and to determine its association with type of organ involvement and gender. Methods: One hundred and fifty-two BS, 51 rheumatoid arthritis (RA), 51 systemic lupus erythematosus (SLE), 51 ankylosing spondylitis (AS) patients and 65 healthy controls were evaluated by the fatigue severity scale, fatigue impact scale, fibromyalgia impact questionnaire (FIQ), RAPID3, SF-36 and Behçet's syndrome activity scale (the latter only in BS patients). We also analysed subgroups of BS patients with predominantly eye, vascular, joint and mucocutaneous involvement and did an additional gender analysis. Results: Fatigue severity and fatigue impact scores were similar among BS, RA, SLE and AS patients and significantly higher than that in healthy controls (F4df=8.51; p<0.001 and F4df=8.67; p<0.001, respectively). The fatigue severity and fatigue impact scores were similarly high in BS subgroups with different types of organ involvement, and in both genders. Conclusions: Fatigue is an important problem in BS, as it is in other inflammatory conditions. It is similarly severe in subgroups of patients with eye, vascular, joint and mucocutaneous involvement and in either gender. Fatigue is a candidate outcome measure for clinical trials, to assess the life impact of Behçet's syndrome.
MeSH term(s)	Adult ; Behcet Syndrome/complications ; Behcet Syndrome/diagnosis ; Behcet Syndrome/psychology ; Case-Control Studies ; Cost of Illness ; Disease Progression ; Fatigue/diagnosis ; Fatigue/etiology ; Fatigue/psychology ; Female ; Health Surveys ; Humans ; Male ; Middle Aged ; Quality of Life ; Risk Factors ; Severity of Illness Index ; Surveys and Questionnaires ; Young Adult
Language	English
Publishing date	2015-11
Publishing country	Italy
Document type	Comparative Study ; Journal Article
ZDB-ID	605886-3
ISSN	1593-098X ; 0392-856X
ISSN (online)	1593-098X
ISSN	0392-856X
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2002: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Preliminary Report of the Academic CAR-T (ISIKOK-19) Cell Clinical Trial in Turkey: Characterization of Product and Outcomes of Clinical Application

Erdoğan, Ebru / Yalçın, Koray / Hemşinlioğlu, Cansu / Sezgin, Aslıhan / Seyis, Utku / Kançağı, Derya Dilek / Taştan, Cihan / Yurtsever, Bulut / Turan, Raife Dilek / Çakırsoy, Didem / Abanuz, Selen / Sır Karakuş, Gözde / Elek, Muhammer / Bekoz, Hüseyin Saffet / Gemici, Ali İhsan / Sargın, Deniz / Arat, Mutlu / Ferhanoğlu, Burhan / Pekgüç, Ebru /

Örnek, Serdar / Büyüktaş, Deram / Birgen, Nur / Ratip, Siret / Ovalı, Ercüment

Turkish journal of haematology : official journal of Turkish Society of Haematology

2022 Volume 39, Issue 3, Page(s) 206–210

Abstract: Objective: Chimeric antigen receptor T (CAR-T) cell therapies have already made an impact on the treatment of B-cell malignancies. Although CAR-T cell therapies are promising, there are concerns about commercial products regarding their affordability ... ...

Abstract	Objective: Chimeric antigen receptor T (CAR-T) cell therapies have already made an impact on the treatment of B-cell malignancies. Although CAR-T cell therapies are promising, there are concerns about commercial products regarding their affordability and sustainability. In this preliminary study, the results of the first production and clinical data of an academic CAR-T cell (ISIKOK-19) trial in Turkey are presented. Materials and methods: A pilot clinical trial (NCT04206943) designed to assess the safety and feasibility of ISIKOK-19 T-cell therapy for patients with relapsed and refractory CD19+ tumors was conducted and participating patients received ISIKOK-19 infusions between October 2019 and July 2021. The production data of the first 8 patients and the clinical outcome of 7 patients who received ISIKOK-19 cell infusions are presented in this study. Results: Nine patients were enrolled in the trial [5 with acute lymphoblastic leukemia (ALL) and 4 with non-Hodgkin lymphoma (NHL)], but only 7 patients could receive treatment. Two of the 3 participating ALL patients and 3 of the 4 NHL patients had complete/partial response (overall response rate: 72%). Four patients (57%) had CAR-T-related toxicities (cytokine release syndrome, CAR-T-related encephalopathy syndrome, and pancytopenia). Two patients were unresponsive and had progressive disease following CAR-T therapy. Two patients with partial response had progressive disease during follow-up. Conclusion: Production efficacy and fulfillment of the criteria of quality control were satisfactory for academic production. Response rates and toxicity profiles were also acceptable for this heavily pretreated/refractory patient group. ISIKOK-19 cells appear to be a safe, economical, and efficient treatment option for CD19+ tumors. However, the findings of this study need to be supported by the currently ongoing ISIKOK-19 clinical trial.
MeSH term(s)	Antigens, CD19 ; Humans ; Immunotherapy, Adoptive/adverse effects ; Immunotherapy, Adoptive/methods ; Lymphoma, Non-Hodgkin/therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/etiology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy ; Receptors, Antigen, T-Cell/genetics ; Receptors, Antigen, T-Cell/therapeutic use ; Receptors, Chimeric Antigen ; Turkey/epidemiology
Chemical Substances	Antigens, CD19 ; Receptors, Antigen, T-Cell ; Receptors, Chimeric Antigen
Language	English
Publishing date	2022-07-18
Publishing country	Turkey
Document type	Clinical Trial ; Journal Article
ZDB-ID	2185903-6
ISSN	1308-5263 ; 1300-7777
ISSN (online)	1308-5263
ISSN	1300-7777
DOI	10.4274/tjh.galenos.2022.2022.0193
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6534: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data.

Birtas Atesoglu, Elif / Gulbas, Zafer / Uzay, Ant / Ozcan, Muhit / Ozkalemkas, Fahir / Dal, Mehmet Sinan / Kalyon, Hakan / Akay, Olga Meltem / Deveci, Burak / Bekoz, Huseyin / Sevindik, Omur Gokmen / Toptas, Tayfur / Yilmaz, Fergun / Koyun, Derya / Alkis, Nihan / Alacacioglu, Inci / Sonmez, Mehmet / Yavasoglu, Irfan / Tombak, Anil /

Mehtap, Ozgur / Kurnaz, Fatih / Yuce, Orhan Kemal / Karakus, Volkan / Turgut, Mehmet / Kurekci, Derya Deniz / Ayer, Mesut / Keklik, Muzaffer / Buyuktas, Deram / Ozbalak, Murat / Ferhanoglu, Burhan

Hematological oncology

2023 Volume 41, Issue 4, Page(s) 663–673

Abstract: Glofitamab is a CD3xCD20 bi-specific antibody with two fragments directed to the CD20 antigen and a single CD3-binding fragment. Encouraging response and survival rates were recently reported in a pivotal phase II expansion trial conducted in patients ... ...

Abstract	Glofitamab is a CD3xCD20 bi-specific antibody with two fragments directed to the CD20 antigen and a single CD3-binding fragment. Encouraging response and survival rates were recently reported in a pivotal phase II expansion trial conducted in patients with relapsed/refractory (R/R) B-cell lymphoma. However, the real-world data of patients of all ages with no strict selection criteria are still lacking. Herein, this retrospective study aimed to evaluate the outcomes of diffuse large B-cell lymphoma (DLBCL) patients who received glofitamab via compassionate use in Turkey. Forty-three patients from 20 centers who received at least one dose of the treatment were included in this study. The median age was 54 years. The median number of previous therapies was 4, and 23 patients were refractory to first-line treatment. Twenty patients had previously undergone autologous stem cell transplantation. The median follow-up time was 5.7 months. In efficacy-evaluable patients, 21% and 16% of them achieved complete response and partial response, respectively. The median response duration was 6.3 months. The median progression-free survival (PFS) and overall survival (OS) was 3.3 and 8.8 months, respectively. None of the treatment-responsive patients progressed during the study period, and their estimated 1-year PFS and OS rate was 83%. The most frequently reported toxicity was hematological toxicity. Sixteen patients survived, while 27 died at the time of the analysis. The most common cause of death was disease progression. One patient died of cytokine release syndrome during the first cycle after receiving the first dose of glofitamab. Meanwhile, two patients died due to glofitamab-related febrile neutropenia. This is the largest real-world study on the effectiveness and toxicity of glofitamab treatment in R/R DLBCL patients. The median OS of 9 months seems promising in this heavily pretreated group. The toxicity related mortality rates were the primary concerns in this study.
Language	English
Publishing date	2023-05-22
Publishing country	England
Document type	Journal Article
ZDB-ID	604884-5
ISSN	1099-1069 ; 0278-0232
ISSN (online)	1099-1069
ISSN	0278-0232
DOI	10.1002/hon.3174
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1816: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito